An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine
about
Structural basis of HIV-1 resistance to AZT by excisionSelection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidineCoresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidineN348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistanceZidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptaseA recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors.Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistanceConvergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies.High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (subtype E) human immunodeficiency virus type 1.Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolates.Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action.HIV research in Australia: linking basic research findings with clinical and public health outcomes.Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.Therapy of HIV Infection: Current Approaches and Prospects.Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants.Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences.A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 2Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.Thymidine analogue excision and discrimination modulated by mutational complexes including single amino acid deletions of Asp-67 or Thr-69 in HIV-1 reverse transcriptase.
P2860
Q24596976-779B5BD9-D814-4790-989C-9E6C86498EFBQ28344137-9945E30A-F208-4B6F-BA6D-B8324EE0D56CQ28369167-50797EB3-B7FC-48DA-8B5C-428C62ECFCCCQ28379499-D3C054C0-3D4D-438C-A88D-D9DB83C63FB1Q28471689-4ED82FB4-0681-4E20-A737-18A70F22436AQ28481004-5C91A868-C031-48A8-80BC-F7DB83DEB227Q32157822-8B438BBB-C22C-4D3D-86A7-FC3926D03E6BQ33667350-4641D7A6-600F-464B-B4B5-267AAA77D24EQ33787173-70C8CB1C-B14E-408F-90BC-B4138ACB343BQ33796791-89128153-471F-4774-8F59-8D6FF682CF2BQ33826453-63E5F940-420A-4F9E-9A9D-6FBB34E9C488Q33841974-89AE8ACE-0037-4F4D-AC73-D2A06F697F54Q33889635-2E831667-BA93-4398-BF44-403F7BB04BABQ33900459-4789475D-FE6A-417A-BD69-21B483ABA67FQ33906239-3F676B89-50AD-49E2-977B-45C895725E94Q34252835-B67395C9-B659-42FC-A7B8-23CFCF32DF23Q34717892-C246DAF4-5E6D-4146-B0B3-A236242CE16CQ35156392-776B5242-DC36-44D2-AC86-CA73B326FD86Q35185934-1A73D823-9558-4FFC-A524-638EC9D57468Q35215246-CC668DB1-F3B1-4383-85FF-CE3DE5010035Q35237036-CF73A78E-4F19-4D30-AC3F-396033EC91E3Q35742512-629B782F-DC1C-4D1E-9D1E-D14BAA7C29A3Q36290768-C64968A1-9A0A-475C-863A-C4791BBC1C24Q36981369-F3DF55D5-E6DF-4FC3-9C1E-FC2B54CD4BBBQ37018369-1F1E8A03-76F5-4212-9605-1517D2BF4748Q37387866-4A980268-D30D-462A-A2AD-B3455D9A6E51Q39066550-C2AEB41A-E13D-4B7D-825A-48045C72675DQ39077432-962A4260-02BE-4171-B120-BA962C0C0ACFQ39142877-B1A571F5-7412-46C2-8919-EAFBA261C829Q39454015-463AA897-1D62-482D-9BC9-95C2A338F0F7Q39471491-61775AF8-676A-4CA4-9EB7-FD27F78DA839Q39557921-4EA059E7-7D0F-426A-906A-BA6EBA4D321AQ39578289-B7465396-AAE2-4765-81CF-C9FE367FF831Q39730755-1295BA23-BFD8-43B2-8A7B-F19F49F9BA12Q40013658-FA8387AD-0E41-4556-AB36-121D262F6D89Q42770670-C1469EEA-6F89-4C43-9681-ED9D99782835
P2860
An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine
description
1996 nî lūn-bûn
@nan
1996 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
An in vivo mutation from leuci ...... to 3'-azido-3'-deoxythymidine
@ast
An in vivo mutation from leuci ...... to 3'-azido-3'-deoxythymidine
@en
An in vivo mutation from leuci ...... to 3'-azido-3'-deoxythymidine
@nl
type
label
An in vivo mutation from leuci ...... to 3'-azido-3'-deoxythymidine
@ast
An in vivo mutation from leuci ...... to 3'-azido-3'-deoxythymidine
@en
An in vivo mutation from leuci ...... to 3'-azido-3'-deoxythymidine
@nl
prefLabel
An in vivo mutation from leuci ...... to 3'-azido-3'-deoxythymidine
@ast
An in vivo mutation from leuci ...... to 3'-azido-3'-deoxythymidine
@en
An in vivo mutation from leuci ...... to 3'-azido-3'-deoxythymidine
@nl
P2093
P2860
P1433
P1476
An in vivo mutation from leuci ...... to 3'-azido-3'-deoxythymidine
@en
P2093
A D Gurusinghe
A E Solomon
D J Hooker
G Tachedjian
J L Anderson
N J Deacon
P2860
P304
P407
P577
1996-11-01T00:00:00Z